Northwest Biotherapeutics issues common stock, warrants in private placement
Insight Weekly: M&A players predict 2023 activity; SPAC IPOs dip; 2022 capacity retirements up
Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share
Northwest Biotherapeutics Inc. sold 5.0 million common shares at 20 cents apiece to an unaffiliated investor.
The company also issued to the investor 2.5 million class D warrants exercisable at 23 cents per share for a period of two years, and 2.5 million class D warrants exercisable at 30 cents per share for a period of two years, for an aggregate of $1.0 million.
